摘要
药物化疗依然是目前癌症最基础的治疗方法之一,然而不同患者对化疗药物的敏感性存在个体间的差异,有些甚至对药物化疗产生耐药,此类问题成为肿瘤临床治疗过程中的棘手问题。近年研究显示,肠道菌群可以通过多种机制调节宿主对化疗的反应,包括免疫相互作用、异质代谢和改变菌落结构,对新近兴起的免疫治疗及化疗药物的疗效发挥关键性的调节作用。笔者介绍临床上使用的传统化疗药物以及新型免疫治疗药物抗CTLA-4以及抗PD-1抗体对肠道菌群的影响,以及此种作用对化疗疗效的影响及其作用机制,以期为以肠道菌群为潜在靶点的癌症治疗提供依据和线索。
Chemotherapeutic drugs play an important role in the treatment of cancer,but the individual differences of patients'sensitivity to chemotherapeutic drugs and the drug resistance of chemotherapeutic drugs have always been a thorny problem in clinical treatment.Recent studies have shown that gut microbiota plays a key role in regulating the efficacy of chemotherapeutic drugs.Gut microbiota can regulate host response to chemotherapy through a variety of mechanisms,including immune interaction,heterogeneous metabolism and changes in community structure.This paper introduces the effects of traditional chemotherapeutic drugs and new immunotherapeutic drugs,such as anti-CTLA-4 and anti-PD-1 antibodies,on gut microbiota,as well as their effects on chemotherapeutic efficacy and mechanism,in order to provide evidences and clues for cancer treatments targeting gut microbiota.
作者
马文兵
卢晓云
禚映辰
郑巧伟
封卫毅
MA Wen-bing;LU Xiao-yun;ZHUO Ying-chen;ZHENG Qiao-wei;FENG Wei-yi(Department of Pharmacology,The First Affliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;The School of Life Science and Technology,Xi'an Jiaotong University,Xi'an 710049,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2020年第12期979-984,共6页
Chinese Pharmaceutical Journal
基金
国家自然科学基金项目资助(81372379,81972814)
西安交通大学第一附属医院院基金项目资助(2017MS-04)。
关键词
肠道菌群
肿瘤生长
化疗药物
免疫疗法
疗效
gut microbiota
tumor growth
chemotherapeutic drug
immunotherapy
effectiveness
